Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Prostaglandin E1 in Outpatients With Intermittent Claudication
NCT01263925Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2001
- Primary completion
- Apr 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Alprostadil Liposomes for Injection in intermittent claudication (IC) (2 arms), sponsored by UCB. Primary endpoints: Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline at 8 weeks, Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at Baseline at 6 months and 1 more. Started Apr 2001; status: completed.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
intermittent claudication (IC)
Beyond the preview
Go deeper on NCT01263925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01263925.